三诺生物收盘下跌1.03%，滚动市盈率37.45倍，总市值118.89亿元

Core Points - The closing price of Sanofi Biologicals on July 30 was 21.22 yuan, down 1.03%, with a rolling PE ratio of 37.45 times and a total market value of 11.889 billion yuan [1] - The average PE ratio in the medical device industry is 55.15 times, with a median of 37.48 times, placing Sanofi Biologicals at the 75th position in the industry ranking [1] - On July 30, the net outflow of main funds for Sanofi Biologicals was 5.5516 million yuan, but over the past five days, there was a total inflow of 61.8244 million yuan [1] - Sanofi Biologicals specializes in the production and sales of blood glucose monitoring systems and has received multiple national recognitions for its technological advancements and innovation [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 1.042 billion yuan, a year-on-year increase of 2.76%, while net profit was 72.1151 million yuan, a year-on-year decrease of 10.90%, with a gross profit margin of 48.69% [1] Industry Summary - The average PE ratio for the medical device industry is 55.15 times, while the median is 37.48 times [2] - The PE ratio for Sanofi Biologicals is 37.45 times, which is below the industry average but aligns with the median [2] - Other companies in the industry have varying PE ratios, with the highest being 20.21 times for Antu Biology and the lowest at 11.07 times for Jiuan Medical [2]